The Motley Fool Previous Page

Tysabri: It's a Blockbuster! Yawn. So What?

Brian Orelli, Ph.D.
January 12, 2010

The financial press can finally drop the "potential" in front of blockbuster when describing Biogen Idec (Nasdaq: BIIB  ) and Elan's (NYSE: ELN  ) multiple sclerosis drug, Tyasbri. As part of the J.P. Morgan Healthcare Conference, Biogen announced that sales of Tysabri had passed the $1 billion mark in 2009, making it an official blockbuster.

Whoopty do.

Whether sales were $1.01 billion or $999 million last year doesn't really matter. The $1 billion in a